How Conditional FDA Approval of Credelio Quattro-CA1 Could Impact Elanco Animal Health (ELAN) Investors

Elanco Animal Health recently received conditional FDA approval for Credelio Quattro-CA1, the first companion animal treatment targeting New World screwworm infestations in dogs, reinforcing its ...

Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro™-CA1 (lotilaner, moxidectin, ...